Drug Profile
Research programme: allergy gene vaccines - Tunitas Therapeutics
Alternative Names: EPLLatest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Tunitas Therapeutics
- Class Gene therapies; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for research development in Allergy in USA (Parenteral)
- 16 Dec 2013 Early research in Hypersensitivity in USA (Parenteral)